CLGN Stock — Collplant Biotechnologies Ltd

Collplant Biotechnologies Ltd (CLGN)

Updated October 16, 2026.

CLGN is a Stock. Total return is -98.0% over the past 11.4 years, 432.6 points behind SPY at 334.6%.

CollPlant Biotechnologies is a regenerative and aesthetic medicine company developing recombinant human collagen-based products for tissue engineering, 3D bioprinting, and wound care applications, with offerings including dermal fillers, bioprinted breast implants, and bioinks for medical use. The company does not currently distribute to shareholders. This business appeals to investors seeking exposure to early-stage biotechnology and regenerative medicine without expectation of dividend income.

CLGN performance versus SPY

Price and return data through 2026-10-16.

Total return is -98.0% over the past 11.4 years, 432.6 points behind SPY at 334.6%. Over the past year its total return — price change plus distributions reinvested — is -84.5%. Its deepest 1-year drawdown was 89.0%.

CLGN key facts

Asset type

Stock

Asset class

Equity

Inception date

05/14/2015

Distribution frequency

None

Last close

$3.62 (as of 2026-10-16)

Market cap

$6,854,226

Average volume

13431.0

Payment date

11/21/2016

Beta

0.743

Payout ratio

0.0%

Forward P/E

80.0

EPS

$-9.50

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CLGN risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 89.0%.

Who may consider CLGN — and who may not

It is a weaker fit for investors who need monthly cash flow (CLGN does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on CLGN

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions